160 related articles for article (PubMed ID: 28567073)
1. Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia.
Ayatollahi H; Sadeghian MH; Naderi M; Jafarian AH; Shams SF; Motamedirad N; Sheikhi M; Bahrami A; Shakeri S
J Res Med Sci; 2017; 22():54. PubMed ID: 28567073
[TBL] [Abstract][Full Text] [Related]
2. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
[TBL] [Abstract][Full Text] [Related]
3. [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients].
Polák J; Marková J; Schwarz J; Maaloufová J; Volková Z; Cermák J; Haskovec C
Cas Lek Cesk; 2006; 145(1):36-42. PubMed ID: 16468240
[TBL] [Abstract][Full Text] [Related]
4. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
5. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
6. WT1 monitoring in core binding factor AML: comparison with specific chimeric products.
Lasa A; Carricondo M; Estivill C; Bussaglia E; Gich I; Brunet S; Aventin A; Sierra J; Nomdedéu JF
Leuk Res; 2009 Dec; 33(12):1643-9. PubMed ID: 19427034
[TBL] [Abstract][Full Text] [Related]
7. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.
Matsuo H; Iijima-Yamashita Y; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):41-46. PubMed ID: 29067751
[TBL] [Abstract][Full Text] [Related]
9. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
Inoue K; Ogawa H; Yamagami T; Soma T; Tani Y; Tatekawa T; Oji Y; Tamaki H; Kyo T; Dohy H; Hiraoka A; Masaoka T; Kishimoto T; Sugiyama H
Blood; 1996 Sep; 88(6):2267-78. PubMed ID: 8822948
[TBL] [Abstract][Full Text] [Related]
11. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.
Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365
[TBL] [Abstract][Full Text] [Related]
13. [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results].
Balwierz W; Pietrzyk JJ; Wator G; Stozek K; Klekawka T; Kwiecińska K; Dłuzniewska A; Matysiak M; Malinowska I; Sikorska-Fic B; Balcerska A; Maciejka-Kapuścińska L; Sońta-Jakimczyk D; Tomaszewska R; Chybicka A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Urasiński T; Kamieńska E; Sobol G; Wieczorek M; Karolczyk G; Wysocki M; Kołtan S; Kowalczyk JR; Wójcik B; Ksiazek T; Szewczyk K
Przegl Lek; 2010; 67(6):371-4. PubMed ID: 21344764
[TBL] [Abstract][Full Text] [Related]
14. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
Kim HR; Shin JH; Lee JN; Lee EY
Korean J Lab Med; 2007 Oct; 27(5):305-12. PubMed ID: 18094593
[TBL] [Abstract][Full Text] [Related]
17. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
[TBL] [Abstract][Full Text] [Related]
18. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
